Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 15, 2009

Sanofi-Aventis to Acquire BiPar in Deal Valued at $500M

Sanofi-Aventis to Acquire BiPar in Deal Valued at $500M

Sanofi agrees to pay BiPar provided milestones are met

  • Sanofi-aventis signed a binding agreement to acquire BiPar Sciences in a deal worth up to $500 million. The purchase price will depend on milestones achieved by BiPar's lead candidate, BSI-201, a potential first-in-class PARP inhibitor.

    BSI-201 is currently in Phase II trials. It is being investigated in metastatic triple negative breast cancer (TNBC), ovarian cancer, and other malignancies. PARP inhibitors reportedly prevent cancer cells from repairing their own DNA and ultimately cause cancer cell death.

    "The acquisition of BiPar, one of the pioneers for novel tumor-selective therapies, is a further step in our company's goal to focus on new approaches to strengthen our oncology R&D portfolio," says Christopher A. Viehbacher, CEO of Sanofi. "This acquisition illustrates our strong commitment to oncology to provide patients, physicians, and public health stakeholders with breakthrough medicines addressing unmet medical needs."

    BSI-201 is a targeted cancer therapy based on an emerging technique called PARP inhibition, says BiPar. The drug is reportedly being studied in breast and ovarian cancer as well as other malignancies.


    Related News
    Sanofi-Aventis to Commercialize AEterna Zentaris’ Late-Stage BPH Drug in the U.S. (Mar. 6, 2009)
    Sanofi-Aventis Ups Bid for Zentiva to $2.63B (Sept. 22, 2008)
    Dyax and Sanofi-Aventis Ink Oncology Antibody Deal Worth $500M (Feb. 12, 2008)
    Sanofi-aventis Inks Partnership with Regeneron Valued at $560M (Nov. 29, 2007)
    BiPar Finds Overexpressed Protein in Specific Cancers (Oct. 26, 2007)

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »